Contact

JERINI PEPTIDE TECHNOLOGIES IS NOW DIN EN ISO 9001:2000 CERTIFIED

Berlin/Germany – March 25, 2004:
Jerini Peptide Technologies (JPT), a subdivision of Jerini AG, providing innovative peptide-based services and products for biomedical research, has been DIN EN ISO 9001:2000 certified.The external certifying body TÜV Rheinland has attested JPT to be in full compliance with DIN EN ISO 9001:2000 requirements. “In order to continuously improve satisfaction of our customers by advancing our in-house proc-esses and quality standards, we started to implement a professional quality management system 18 month ago and are extremely pleased that the system was awarded by an official certification subsequent to an independent audit procedure”, said Dr. Holger Wenschuh, Head of Jerini Peptide Technologies. The DIN EN ISO 9001:2000 standard was developed to help manufacturers and service providers in the international marketplace develop a quality conscious approach for their research, testing, manufacturing and support operations. Furthermore ISO 9001 ensures continual improvement of processes, a continued high quality standard as well as increased customer satisfaction. More and more customers are requiring that their suppliers are certified.

About Jerini Peptide Technologies

Jerini Peptide Technologies (JPT) provides innovative peptide related services for all fields of biomedical research. Numerous proprietary technologies and products including JPT’s high throughput peptide synthesis and screening platform make JPT a unique partner for tailor-made peptide tools and custom synthesis.

About Jerini AG

Jerini AG is a drug discovery and development company based and founded in 1994 in Berlin, Germany. The company has built a pipeline of several preclinical and two clinical projects (phase IIa) with its proprie-tary discovery platform including SPOT, pepSTAR™ and pepMED™. The platform enables massive parallel syntheses and screening of peptide leads, pharmacophore identification and transformation into pepti-domimetic and small molecule drugs. The peptide lead to small molecule conversion process is supported by medicinal chemistry and cheminformatics and guided by matching the pharmacophore derived from mas-sive peptide SAR data information against a virtual small molecule library. Jerini’s platform allows the rapid identification and/or optimization of agonists and antagonists for (difficult) target proteins. The technology has been successfully demonstrated in in-house and partnered programs for highly valuable, but difficult targets where conventional methods have failed. Jerini’s approach creates value by reducing time and costs and by decreasing attrition rates. Find more information on www.jerini.com or feel free to contact us.

For further information please contact:

JPT Peptide Technologies GmbH
Dr. Holger Wenschuh
Managing Director
Volmerstr. 5
12489 Berlin/Germany
Phone: +49 - 30 - 6392 - 7880
Fax: +49 - 30 - 6392 - 5501
wenschuh@jpt.com

Stay in touch and be the first to receive the latest news!